Pascal Espié

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng et al. · The Lancet Rheumatology · 2020 · 126 citations

Life Sciences, Clinical Sciences, Immunology +14

Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects

Maria Laura Sargentini‐Maier, Pascal Espié, Alain Coquette et al. · Drug Metabolism and Disposition · 2007 · 115 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial

George J. Kahaly, Marius N. Stan, Lara Frommer et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 96 citations

Life Sciences, Endocrinology, Immunology +17

Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody

Jacinda Ristov, Pascal Espié, Peter Ulrich et al. · American Journal of Transplantation · 2018 · 91 citations · Full text

Life Sciences, Immunology, Pathology +17

First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody

Pascal Espié, Yanling He, Phillip J. Koo et al. · American Journal of Transplantation · 2019 · 91 citations

Medicine, Pharmacokinetics, Pharmacology +17